ScripInsmed capitalized on the company’s better-than-expected Phase IIb clinical trial readout for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH), which sent its s
ScripInsmed may be making a best-in-class case in pulmonary arterial hypertension (PAH) for its inhaled powder formulation of treprostinil, the active ingredient in United Therapeutics’ blockbuster Tyvaso.
Pink SheetThe European Medicines Agency was this week deciding whether the planned EU marketing authorization applications (MAAs) for three investigational products deserved accelerated assessments – apitegroma
ScripNot even two months into the new year and some of the expected biggest-earning new drugs of 2025 have already been approved. An updated analysis conducted by Scrip and Evaluate Pharma of drugs expec